id,guidelineid,drugid,implications,drugrecommendation,classification,phenotypes,activityscore,allelestatus,lookupkey,population,comments,version,dosinginformation,alternatedrugavailable,otherprescribingguidance
4167629,100421,RxNorm:190521,{'HLA-B': 'Low or reduced risk of abacavir hypersensitivity'},Use abacavir per standard dosing guidelines,Strong,{},{},{'HLA-B': 'HLA-B*57:01 negative'},{'HLA-B': '*57:01 negative'},general,n/a,1,False,False,False
4167630,100421,RxNorm:190521,{'HLA-B': 'Significantly increased risk of abacavir hypersensitivity'},Abacavir is not recommended,Strong,{},{},{'HLA-B': 'HLA-B*57:01 positive'},{'HLA-B': '*57:01 positive'},general,n/a,1,False,False,False
4167631,100422,RxNorm:519,{'HLA-B': 'Low or reduced risk of allopurinol-induced SCAR'},Use allopurinol per standard dosing guidelines,Strong,{},{},{'HLA-B': 'HLA-B*58:01 negative'},{'HLA-B': '*58:01 negative'},general,n/a,1,False,False,False
4167632,100422,RxNorm:519,{'HLA-B': 'Significantly increased risk of allopurinol-induced SCAR'},Allopurinol is contraindicated,Strong,{},{},{'HLA-B': 'HLA-B*58:01 positive'},{'HLA-B': '*58:01 positive'},general,n/a,1,False,False,False
4167633,826283,RxNorm:641,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167634,826283,RxNorm:641,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167635,826283,RxNorm:641,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167636,826283,ATC:D06AX07,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167637,826283,ATC:D06AX07,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167638,826283,ATC:D06AX07,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167639,826283,RxNorm:6099,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167640,826283,RxNorm:6099,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167641,826283,RxNorm:6099,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167642,826283,RxNorm:7934,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167643,826283,RxNorm:7934,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167644,826283,RxNorm:7934,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167645,826283,RxNorm:2049549,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167646,826283,RxNorm:2049549,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167647,826283,RxNorm:2049549,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167648,826283,RxNorm:10109,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167649,826283,RxNorm:10109,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167650,826283,RxNorm:10109,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167651,826283,RxNorm:10627,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4168079,2405438,RxNorm:1151,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167652,826283,RxNorm:10627,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167653,826283,RxNorm:10627,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167654,826283,RxNorm:3328,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167655,826283,RxNorm:3328,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167656,826283,RxNorm:3328,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167657,826283,RxNorm:7299,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167658,826283,RxNorm:7299,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167659,826283,RxNorm:7299,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167660,826283,RxNorm:7337,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167661,826283,RxNorm:7337,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167677,2405438,RxNorm:3445,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167662,826283,RxNorm:7337,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167663,826283,RxNorm:NA,{'MT-RNR1': 'Very high risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.,Strong,{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},general,"If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).",1,False,False,False
4167664,826283,RxNorm:NA,{'MT-RNR1': 'Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Strong,{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167665,826283,RxNorm:NA,{'MT-RNR1': 'Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic.'},Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.,Optional,{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},general,"Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.",1,False,False,False
4167666,2405438,RxNorm:7833,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167667,2405438,RxNorm:7833,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167668,2405438,RxNorm:7833,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167669,2405438,RxNorm:7833,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167670,2405438,RxNorm:7833,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167671,2405438,RxNorm:2551,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167672,2405438,RxNorm:2551,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167673,2405438,RxNorm:2551,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167674,2405438,RxNorm:2551,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167675,2405438,RxNorm:2551,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167676,2405438,RxNorm:3445,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167696,2405438,RxNorm:6572,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167678,2405438,RxNorm:3445,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167679,2405438,RxNorm:3445,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167680,2405438,RxNorm:3445,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167681,2405438,RxNorm:3639,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167682,2405438,RxNorm:3639,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167683,2405438,RxNorm:3639,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167684,2405438,RxNorm:3639,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167685,2405438,RxNorm:3639,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167686,2405438,RxNorm:4601,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167687,2405438,RxNorm:4601,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167688,2405438,RxNorm:4601,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167689,2405438,RxNorm:4601,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167690,2405438,RxNorm:4601,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167691,2405438,RxNorm:4815,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167692,2405438,RxNorm:4815,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167693,2405438,RxNorm:4815,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167694,2405438,RxNorm:4815,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167695,2405438,RxNorm:4815,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167697,2405438,RxNorm:6572,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167698,2405438,RxNorm:6572,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167699,2405438,RxNorm:6572,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167700,2405438,RxNorm:6572,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167701,2405438,RxNorm:7240,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167702,2405438,RxNorm:7240,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167703,2405438,RxNorm:7240,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167704,2405438,RxNorm:7240,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167705,2405438,RxNorm:7240,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167706,2405438,RxNorm:7517,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167707,2405438,RxNorm:7517,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167708,2405438,RxNorm:7517,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4167709,2405438,RxNorm:7517,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167710,2405438,RxNorm:7517,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167711,2405438,RxNorm:7623,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167712,2405438,RxNorm:7623,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4167713,2405438,RxNorm:7623,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4168080,2405438,RxNorm:1151,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4167714,2405438,RxNorm:7623,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167715,2405438,RxNorm:7623,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167716,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167717,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167718,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167719,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167720,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167721,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169158,2405438,RxNorm:9071,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4167722,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167723,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167724,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167725,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167726,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167727,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167728,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167729,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167758,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167730,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167731,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167732,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167733,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167734,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167735,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167736,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167737,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,No Recommendation,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4167738,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167739,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167740,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167741,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167742,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167743,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167744,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167745,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167746,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167747,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167759,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167748,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167749,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167750,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167751,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167752,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167753,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167754,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167755,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167756,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167757,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167760,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",No recommendation,No Recommendation,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4167761,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167762,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167763,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167764,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167765,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167841,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167766,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167767,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167768,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167769,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167770,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167771,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167987,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4167772,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167773,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167774,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167775,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167776,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167777,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167778,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167779,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167780,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167781,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167782,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167783,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Moderate,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167784,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Moderate,"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167785,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167786,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167787,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167788,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167842,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167789,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167790,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167791,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167792,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167793,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167794,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167843,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167795,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167796,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167797,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167798,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167799,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167800,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167801,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167802,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167803,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167804,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167805,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167806,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169418,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4167807,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4167808,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167809,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167810,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167811,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167812,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167813,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167814,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167815,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167816,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167817,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167818,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167861,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167819,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167820,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167821,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167822,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167823,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167824,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167825,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167826,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167827,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167828,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4167829,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4167830,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168067,2405438,RxNorm:2348,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167831,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167832,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167833,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167834,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167835,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167836,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167837,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167838,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167839,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167840,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168068,2405438,RxNorm:2348,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167844,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167845,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167846,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167847,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167848,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167849,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167850,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167851,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167852,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167853,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4167862,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167854,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167855,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167856,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167857,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167858,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167859,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167860,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168070,2405438,RxNorm:2393,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4167863,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167864,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167865,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167866,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167867,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167868,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167869,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167930,100429,RxNorm:343047,{'UGT1A1': 'n/a'},No recommendation,No Recommendation,{'UGT1A1': 'Indeterminate'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Indeterminate'},general,"UGT1A1*80 is in very high linkage disequilibrium with *28 and *37. In the rare event that *80 is detected but *28 and *37 are not, there are not enough clinical data to predict metabolizer status with certainty. However, if only *80 is interrogated and the patient is heterozygous or homozygous for *80, an intermediate or poor metabolizer phenotype may be inferred, respectively.",1,False,False,False
4167870,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167871,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167872,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167873,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167874,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167875,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,No Recommendation,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4167876,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167877,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169483,100416,RxNorm:10689,{'CYP2D6': 'Expected O-desmethyltramadol (active metabolite) formation'},Use tramadol label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4167878,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167879,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167880,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167881,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167882,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167986,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4167883,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167884,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167885,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Moderate,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167886,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167887,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167888,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169419,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4167889,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167890,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167891,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167892,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167893,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167894,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167895,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167896,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167897,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4167898,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Moderate,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167899,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Moderate,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167900,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167901,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167902,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167903,100414,RxNorm:704,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Moderate,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4167904,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167905,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167906,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167907,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167908,100414,RxNorm:704,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4167909,100414,RxNorm:704,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168071,2405438,RxNorm:2393,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis",1,False,False,False
4167910,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167911,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167912,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167913,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167914,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167915,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167916,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167917,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167918,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168072,2405438,RxNorm:2393,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167919,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167920,100414,RxNorm:704,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Strong,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167921,100414,RxNorm:704,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4167922,2405438,RxNorm:1191,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},<= 1g per day,aspirin ≤ 1 g/day,1,False,False,False
4167923,2405438,RxNorm:1191,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},<= 1g per day,"aspirin ≤ 1 g/day. Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4167924,2405438,RxNorm:1191,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},<= 1g per day,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4167925,2405438,RxNorm:1191,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},<= 1g per day,"aspirin ≤ 1 g/day. Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167926,2405438,RxNorm:1191,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},<= 1g per day,aspirin ≤ 1 g/day,1,False,False,False
4167927,100429,RxNorm:343047,{'UGT1A1': 'Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.'},"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",Strong,{'UGT1A1': 'Normal Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Normal Metabolizer'},general,"All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat. ""reference"" function refers to the UGT1A1 allele to which other alleles are compared.",1,False,False,False
4167928,100429,RxNorm:343047,{'UGT1A1': 'Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.'},"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",Strong,{'UGT1A1': 'Intermediate Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Intermediate Metabolizer'},general,"All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.",1,False,False,False
4167929,100429,RxNorm:343047,{'UGT1A1': 'Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir.'},"Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).",Strong,{'UGT1A1': 'Poor Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Poor Metabolizer'},general,"All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.",1,False,False,False
4167931,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167932,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167933,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167934,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167935,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167936,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167937,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167938,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167939,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167940,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167941,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167942,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167943,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167944,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167945,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167946,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167947,104243,RxNorm:38400,{'CYP2D6': 'Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167948,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167949,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167950,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167951,104243,RxNorm:38400,"{'CYP2D6': 'Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.'}","Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Strong,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},pediatrics,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167952,104243,RxNorm:38400,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},pediatrics,n/a,1,False,False,False
4167953,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167954,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4169420,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4167955,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167956,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167957,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167958,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167959,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4168073,2405438,RxNorm:2393,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4167960,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167961,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167962,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167963,104243,RxNorm:38400,"{'CYP2D6': 'Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.'}","Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167964,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4168075,2405438,RxNorm:5521,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4167965,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167966,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167967,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167968,104243,RxNorm:38400,{'CYP2D6': 'Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4167969,104243,RxNorm:38400,{'CYP2D6': 'Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",1,False,False,False
4168746,100413,RxNorm:42355,{'CYP2D6': 'Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4167970,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167971,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167972,104243,RxNorm:38400,{'CYP2D6': 'Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.'},"Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167973,104243,RxNorm:38400,"{'CYP2D6': 'Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.'}","Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",Moderate,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},adults,"Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",1,False,False,False
4167974,104243,RxNorm:38400,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},adults,n/a,1,False,False,False
4167975,100426,RxNorm:83367,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Increased Function'},{},{},{'SLCO1B1': 'Increased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4167976,100426,RxNorm:83367,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Normal Function'},{},{},{'SLCO1B1': 'Normal Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4167977,100426,RxNorm:83367,{'SLCO1B1': 'Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,{'SLCO1B1': 'Possible Decreased Function'},{},{},{'SLCO1B1': 'Possible Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4167978,100426,RxNorm:83367,{'SLCO1B1': 'Increased atorvastatin exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,{'SLCO1B1': 'Decreased Function'},{},{},{'SLCO1B1': 'Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4167979,100426,RxNorm:83367,{'SLCO1B1': 'Increased atorvastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.'},"Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,{'SLCO1B1': 'Poor Function'},{},{},{'SLCO1B1': 'Poor Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4167980,100426,RxNorm:83367,{'SLCO1B1': 'n/a'},No recommendation,No Recommendation,{'SLCO1B1': 'Indeterminate'},{},{},{'SLCO1B1': 'Indeterminate'},general,n/a,1,False,False,False
4167981,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4167982,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167983,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167984,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167985,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167988,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167989,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167990,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167991,100428,RxNorm:1256,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4167992,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4167993,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4168077,2405438,RxNorm:5521,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4167994,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4167995,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4167996,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4167997,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4167998,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4167999,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4168021,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 negative', 'HLA-B': 'No Result'}",CBZ naive,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168000,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168001,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168002,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4168003,100428,RxNorm:1256,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168004,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168005,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168006,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168078,2405438,RxNorm:5521,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168007,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168008,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168009,100428,RxNorm:1256,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168010,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168011,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168012,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168020,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 positive'}",CBZ naive,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168013,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168014,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168015,100428,RxNorm:1256,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168016,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 negative'}",CBZ naive,"Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",1,False,False,False
4168017,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 negative'}",CBZ naive,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168018,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 positive'}",CBZ naive,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168019,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 positive'}",CBZ naive,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168022,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}","If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 positive', 'HLA-B': 'No Result'}",CBZ naive,"Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",1,False,False,False
4168023,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 negative'}",CBZ naive,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168024,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 negative'}",CBZ-no alternatives,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168025,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 negative'}",CBZ-no alternatives,n/a,1,False,False,False
4168026,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 negative'}",CBZ-no alternatives,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168027,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 positive'}",CBZ-no alternatives,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168028,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 positive'}",CBZ-no alternatives,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168029,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","If patient is carbamazepine-naïve, do not use carbamazepine.",Strong,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 positive'}",CBZ-no alternatives,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168030,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 negative', 'HLA-B': 'No Result'}",CBZ-no alternatives,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168031,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}","If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 positive', 'HLA-B': 'No Result'}",CBZ-no alternatives,n/a,1,False,False,False
4168032,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 negative'}",CBZ use >3mos ,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168033,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}","The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 negative'}",CBZ use >3mos ,"Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",1,False,False,False
4168034,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Normal risk of carbamazepine-induced SJS/TEN'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 negative'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 negative'}",CBZ use >3mos ,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168035,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 positive'}",CBZ use >3mos ,"Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168036,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 positive'}",CBZ use >3mos ,"Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168046,110058,RxNorm:4502,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4168076,2405438,RxNorm:5521,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis",1,False,False,False
4168037,100423,RxNorm:2002,"{'HLA-A': 'n/a', 'HLA-B': 'Greater risk of carbamazepine-induced SJS/TEN'}","The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",Optional,{},{},"{'HLA-A': 'No HLA-A Result', 'HLA-B': 'HLA-B*15:02 positive'}","{'HLA-A': 'No Result', 'HLA-B': '*15:02 positive'}",CBZ use >3mos ,"Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",1,False,False,False
4168038,100423,RxNorm:2002,"{'HLA-A': 'Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}",Use carbamazepine per standard dosing guidelines.,Strong,{},{},"{'HLA-A': 'HLA-A*31:01 negative', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 negative', 'HLA-B': 'No Result'}",CBZ use >3mos ,"HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",1,False,False,False
4168039,100423,RxNorm:2002,"{'HLA-A': 'Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE', 'HLA-B': 'n/a'}","The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",Optional,{},{},"{'HLA-A': 'HLA-A*31:01 positive', 'HLA-B': 'No HLA-B Result'}","{'HLA-A': '*31:01 positive', 'HLA-B': 'No Result'}",CBZ use >3mos ,"Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",1,False,False,False
4168040,110058,RxNorm:140587,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4168041,110058,RxNorm:140587,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168042,110058,RxNorm:140587,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168043,110058,RxNorm:140587,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168044,110058,RxNorm:140587,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168045,110058,RxNorm:140587,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168047,110058,RxNorm:4502,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168048,110058,RxNorm:4502,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168049,110058,RxNorm:4502,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168050,110058,RxNorm:4502,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168051,110058,RxNorm:4502,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168052,110058,RxNorm:5640,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4168053,110058,RxNorm:5640,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168054,110058,RxNorm:5640,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168055,110058,RxNorm:5640,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168056,110058,RxNorm:5640,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168057,110058,RxNorm:5640,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168058,110058,RxNorm:20890,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4168059,110058,RxNorm:20890,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168060,110058,RxNorm:20890,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.,1,False,False,False
4168061,110058,RxNorm:20890,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168062,110058,RxNorm:20890,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168063,110058,RxNorm:20890,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168064,2405438,RxNorm:2348,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168065,2405438,RxNorm:2348,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4168066,2405438,RxNorm:2348,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis",1,False,False,False
4168069,2405438,RxNorm:2393,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168074,2405438,RxNorm:5521,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168081,2405438,RxNorm:1151,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis",1,False,False,False
4168082,2405438,RxNorm:1151,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4168083,2405438,RxNorm:1151,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168084,2405438,RxNorm:11258,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168085,2405438,RxNorm:11258,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs",1,False,False,False
4168086,2405438,RxNorm:11258,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis",1,False,False,False
4168087,2405438,RxNorm:11258,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4168088,2405438,RxNorm:11258,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168089,100413,RxNorm:2556,{'CYP2C19': 'Increased metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 rapid and normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",Strong,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4168090,100413,RxNorm:2556,{'CYP2C19': 'Increase in metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4168091,100413,RxNorm:2556,{'CYP2C19': 'Normal metabolism'},Initiate therapy with recommended starting dose,Strong,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4168092,100413,RxNorm:2556,{'CYP2C19': 'Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Moderate,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose.",1,False,False,False
4168093,100413,RxNorm:2556,{'CYP2C19': 'Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Moderate,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose.",1,False,False,False
4168094,100413,RxNorm:2556,{'CYP2C19': 'Reduced metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal and intermediate metabolizers. Higher plasma concentrations may increase the probability of side effects.'},"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",Strong,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.",1,False,False,False
4168095,100413,RxNorm:2556,{'CYP2C19': 'Reduced metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal and intermediate metabolizers. Higher plasma concentrations may increase the probability of side effects.'},"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",Strong,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,"Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.",1,False,False,False
4168096,100413,RxNorm:2556,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4168097,100413,RxNorm:321988,{'CYP2C19': 'Increased metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 rapid and normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.",Strong,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4168098,100413,RxNorm:321988,{'CYP2C19': 'Increase in metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4168099,100413,RxNorm:321988,{'CYP2C19': 'Normal metabolism'},Initiate therapy with recommended starting dose,Strong,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4168100,100413,RxNorm:321988,{'CYP2C19': 'Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Moderate,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose.",1,False,False,False
4168101,100413,RxNorm:321988,{'CYP2C19': 'Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Moderate,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose.",1,False,False,False
4168102,100413,RxNorm:321988,{'CYP2C19': 'Reduced metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal and intermediate metabolizers. Higher plasma concentrations may increase the probability of side effects.'},"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",Strong,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.",1,False,False,False
4168103,100413,RxNorm:321988,{'CYP2C19': 'Reduced metabolism of citalopram and escitalopram to less active compounds when compared to CYP2C19 normal and intermediate metabolizers. Higher plasma concentrations may increase the probability of side effects.'},"Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.",Strong,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,"Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.",1,False,False,False
4168104,100413,RxNorm:321988,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4168111,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168105,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168106,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168107,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168108,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168109,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168110,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169421,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4168112,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168113,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168114,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168115,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168116,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168747,100413,RxNorm:42355,{'CYP2D6': 'Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4168117,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168118,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168119,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168120,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168121,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168150,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169433,110058,RxNorm:37790,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168122,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168123,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168124,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168125,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168126,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168127,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168128,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168129,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168130,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168131,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168132,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168138,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168133,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168134,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168135,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168136,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168137,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168770,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4168139,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168140,100414,RxNorm:2597,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168141,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168142,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168143,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168144,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168145,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168146,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168147,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168148,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168149,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168151,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168152,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168153,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168154,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168155,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168156,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168175,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168157,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168158,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168159,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168160,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168161,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168162,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168184,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168771,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4168163,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168164,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168165,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168166,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168167,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168168,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168169,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168170,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168171,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168172,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168173,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168174,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168176,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168177,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168178,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168179,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168180,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168181,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168182,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168183,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168185,100414,RxNorm:2597,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168186,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168187,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168188,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168189,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168190,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168197,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168191,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168192,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168193,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168194,100414,RxNorm:2597,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168195,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168196,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168206,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168198,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168199,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168200,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168201,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168202,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168203,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168204,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168205,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168207,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168208,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168209,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168210,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168211,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168212,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168213,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168214,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168215,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168216,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168254,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168217,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168218,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168219,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168220,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168221,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168222,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168223,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168224,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168225,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168226,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168227,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168228,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168229,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168230,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168231,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168232,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168233,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168234,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168235,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168236,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168237,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168238,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168239,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168240,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168241,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168242,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168243,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168244,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168245,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168246,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168247,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168248,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168249,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168250,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168251,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168252,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168253,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168304,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168255,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168256,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168257,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168258,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168259,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168260,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168261,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168262,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168263,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168264,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168265,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168266,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168267,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168268,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168269,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168270,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168271,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168272,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168273,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168274,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168275,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168276,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168277,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168278,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168279,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168280,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168281,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168282,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168283,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168354,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4168284,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168285,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168286,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168287,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168288,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168289,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168290,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168291,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168292,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168355,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4168293,100414,RxNorm:2597,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168294,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168295,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",No recommendation,Strong,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168296,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168297,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168298,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168299,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168300,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168301,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168302,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168303,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168305,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168306,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168307,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168308,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168309,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168310,100414,RxNorm:2597,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168311,100411,RxNorm:32968,{'CYP2C19': 'Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk'},"If considering clopidogrel, use at standard dose (75 mg/day)",Strong,{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},CVI ACS PCI ,For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.,1,False,False,False
4168312,100411,RxNorm:32968,{'CYP2C19': 'Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk'},"If considering clopidogrel, use at standard dose (75 mg/day)",Strong,{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},CVI ACS PCI ,For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.,1,False,False,False
4168313,100411,RxNorm:32968,{'CYP2C19': 'Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity'},"If considering clopidogrel, use at standard dose (75 mg/day)",Strong,{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},CVI ACS PCI ,For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.,1,False,False,False
4168356,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4168314,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Strong,{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},CVI ACS PCI ,"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168315,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Strong,{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},CVI ACS PCI ,For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.,1,False,False,False
4168316,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Strong,{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},CVI ACS PCI ,"For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168317,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Strong,{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},CVI ACS PCI ,For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.,1,False,False,False
4168318,100411,RxNorm:32968,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},CVI ACS PCI ,n/a,1,False,False,False
4168319,100411,RxNorm:32968,{'CYP2C19': 'Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk'},No recommendation,No Recommendation,{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",1,False,False,False
4168320,100411,RxNorm:32968,{'CYP2C19': 'Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk'},No recommendation,No Recommendation,{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",1,False,False,False
4168321,100411,RxNorm:32968,{'CYP2C19': 'Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity'},"If considering clopidogrel, use at standard dose (75 mg/day)",Strong,{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",1,False,False,False
4168322,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},No recommendation,No Recommendation,{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168323,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},No recommendation,No Recommendation,{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",1,False,False,False
4168358,2405438,RxNorm:3108,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Strong,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,,1,False,False,False
4168359,2405438,RxNorm:3108,{'G6PD': 'High risk of acute eacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",1,False,False,False
4168324,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168325,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.,Moderate,{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},CVI non-ACS non-PCI,"For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.",1,False,False,False
4168326,100411,RxNorm:32968,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},CVI non-ACS non-PCI,n/a,1,False,False,False
4168327,100411,RxNorm:32968,{'CYP2C19': 'Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity'},No recommendation,No Recommendation,{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.",1,False,False,False
4168328,100411,RxNorm:32968,{'CYP2C19': 'Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity'},No recommendation,No Recommendation,{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.",1,False,False,False
4168329,100411,RxNorm:32968,{'CYP2C19': 'Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity'},"If considering clopidogrel, use at standard dose (75 mg/day)",Strong,{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.",1,False,False,False
4168330,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.,Moderate,{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168331,100411,RxNorm:32968,{'CYP2C19': 'Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.,Moderate,{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events.",1,False,False,False
4168332,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.,Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168333,100411,RxNorm:32968,{'CYP2C19': 'Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events'},Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.,Moderate,{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},NVI,"For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events.",1,False,False,False
4168334,100411,RxNorm:32968,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},NVI,n/a,1,False,False,False
4168335,100416,RxNorm:2670,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4168336,100416,RxNorm:2670,{'CYP2D6': 'Reduced morphine formation'},"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4168337,100416,RxNorm:2670,{'CYP2D6': 'Reduced morphine formation'},"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4168338,100416,RxNorm:2670,{'CYP2D6': 'Reduced morphine formation'},"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4168339,100416,RxNorm:2670,{'CYP2D6': 'Reduced morphine formation'},"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4168340,100416,RxNorm:2670,{'CYP2D6': 'Expected morphine formation'},Use codeine label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4168341,100416,RxNorm:2670,{'CYP2D6': 'Expected morphine formation'},Use codeine label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4168342,100416,RxNorm:2670,{'CYP2D6': 'Expected morphine formation'},Use codeine label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4168343,100416,RxNorm:2670,{'CYP2D6': 'Expected morphine formation'},Use codeine label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4168344,100416,RxNorm:2670,{'CYP2D6': 'Expected morphine formation'},Use codeine label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4168345,100416,RxNorm:2670,{'CYP2D6': 'Greatly reduced morphine formation leading to diminished analgesia.'},"Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,n/a,1,False,False,False
4168346,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4168347,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4168348,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4168349,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4168350,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4168351,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4168352,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4168353,100416,RxNorm:2670,{'CYP2D6': 'Increased formation of morphine leading to higher risk of toxicity'},"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4168357,2405438,RxNorm:3108,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168360,2405438,RxNorm:3108,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.",1,False,False,False
4168361,2405438,RxNorm:3108,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168362,2405438,RxNorm:1011650,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168363,2405438,RxNorm:1011650,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Strong,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,,1,False,False,False
4168364,2405438,RxNorm:1011650,{'G6PD': 'High risk of acute eacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",1,False,False,False
4168365,2405438,RxNorm:1011650,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.",1,False,False,False
4168366,2405438,RxNorm:1011650,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168367,2405438,RxNorm:283821,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4168368,2405438,RxNorm:283821,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Strong,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,,1,False,False,False
4168369,2405438,RxNorm:283821,{'G6PD': 'High risk of acute eacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",1,False,False,False
4168370,2405438,RxNorm:283821,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.",1,False,False,False
4168371,2405438,RxNorm:283821,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168372,100427,RxNorm:27340,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168378,100427,RxNorm:27340,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168501,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168373,100427,RxNorm:27340,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168374,100427,RxNorm:27340,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168375,100427,RxNorm:27340,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168376,100427,RxNorm:27340,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168377,100427,RxNorm:27340,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4169159,2405438,RxNorm:9071,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4168379,100427,RxNorm:27340,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168380,100427,RxNorm:3920,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168381,100427,RxNorm:3920,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168382,100427,RxNorm:3920,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168383,100427,RxNorm:3920,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168394,100427,RxNorm:5095,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168384,100427,RxNorm:3920,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168385,100427,RxNorm:3920,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168386,100427,RxNorm:3920,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168387,100427,RxNorm:3920,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168388,100427,RxNorm:5095,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168395,100427,RxNorm:5095,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168418,100427,RxNorm:36453,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168389,100427,RxNorm:5095,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168390,100427,RxNorm:5095,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168391,100427,RxNorm:5095,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168392,100427,RxNorm:5095,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168393,100427,RxNorm:5095,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4169177,2405438,RxNorm:10831,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168396,100427,RxNorm:6026,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168397,100427,RxNorm:6026,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168398,100427,RxNorm:6026,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168399,100427,RxNorm:6026,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168400,100427,RxNorm:6026,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168401,100427,RxNorm:6026,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168402,100427,RxNorm:6026,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168403,100427,RxNorm:6026,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168404,100427,RxNorm:6857,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168405,100427,RxNorm:6857,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168406,100427,RxNorm:6857,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4169179,2405438,RxNorm:10184,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4168407,100427,RxNorm:6857,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168408,100427,RxNorm:6857,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168409,100427,RxNorm:6857,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168410,100427,RxNorm:6857,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168411,100427,RxNorm:6857,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168417,100427,RxNorm:36453,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168412,100427,RxNorm:36453,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168413,100427,RxNorm:36453,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168414,100427,RxNorm:36453,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168415,100427,RxNorm:36453,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168416,100427,RxNorm:36453,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168419,100427,RxNorm:36453,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168420,100427,RxNorm:10154,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168421,100427,RxNorm:10154,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168422,100427,RxNorm:10154,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168423,100427,RxNorm:10154,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 or CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168432,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4168424,100427,RxNorm:10154,"{'RYR1': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine', 'CACNA1S': 'n/a'}","Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'No Result'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168425,100427,RxNorm:10154,"{'RYR1': 'n/a', 'CACNA1S': 'Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine'}","Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",general,"A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in CACNA1S generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",1,False,False,False
4168426,100427,RxNorm:10154,"{'RYR1': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).', 'CACNA1S': 'n/a'}","No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",general,n/a,1,False,False,False
4168427,100427,RxNorm:10154,"{'RYR1': 'n/a', 'CACNA1S': 'These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).'}","No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",Strong,"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",general,n/a,1,False,False,False
4168428,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4168429,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4168430,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4168431,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4169197,2405438,RxNorm:10635,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4168433,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4168434,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4168435,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4168436,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4168437,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4168438,100414,RxNorm:3247,{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4168439,100414,RxNorm:3247,{'CYP2D6': 'Normal metabolism of TCAs'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168440,100414,RxNorm:3247,{'CYP2D6': 'Normal metabolism of TCAs'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168441,100414,RxNorm:3247,{'CYP2D6': 'Normal metabolism of TCAs'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168442,100414,RxNorm:3247,{'CYP2D6': 'Normal metabolism of TCAs'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168443,100414,RxNorm:3247,{'CYP2D6': 'Normal metabolism of TCAs'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168444,100414,RxNorm:3247,{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168445,100414,RxNorm:3247,{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168446,100414,RxNorm:3247,{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168447,100414,RxNorm:3247,{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168448,100414,RxNorm:3247,{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168449,100414,RxNorm:3247,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4168450,110076,RxNorm:816346,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,n/a,1,False,False,False
4168451,110076,RxNorm:816346,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Optional,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,n/a,1,False,False,False
4168452,110076,RxNorm:816346,{'CYP2C19': 'Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Optional,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4168453,110076,RxNorm:816346,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168454,110076,RxNorm:816346,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,n/a,1,False,False,False
4168496,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168455,110076,RxNorm:816346,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4168456,110076,RxNorm:816346,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,n/a,1,False,False,False
4168457,110076,RxNorm:816346,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4168458,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168459,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168460,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168461,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168497,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169476,100416,RxNorm:10689,{'CYP2D6': 'Reduced O-desmethyltramadol (active metabolite) formation'},"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4168462,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168463,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168464,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168465,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168466,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168467,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168981,100426,RxNorm:6472,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Normal Function'},{},{},{'SLCO1B1': 'Normal Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168468,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168469,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168470,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168471,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168472,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169079,110076,RxNorm:40790,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,n/a,1,False,False,False
4168473,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168474,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168475,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168476,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168477,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168498,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168478,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168479,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168480,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168481,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168482,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168483,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168499,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168484,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168485,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168486,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168487,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168488,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168489,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168490,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168491,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168492,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168493,100414,RxNorm:3638,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168494,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168495,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168500,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168502,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168503,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168504,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168505,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168506,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168507,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168508,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168526,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168509,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168510,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168511,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168512,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168513,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168514,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168527,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168515,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168516,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168517,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168518,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168519,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168520,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168521,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168522,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168523,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168524,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168525,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169477,100416,RxNorm:10689,{'CYP2D6': 'Reduced O-desmethyltramadol (active metabolite) formation'},"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4168528,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168529,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168530,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168531,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168532,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168533,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168534,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168535,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168536,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168537,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168538,100414,RxNorm:3638,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168539,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168540,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168541,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168542,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168549,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168543,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168544,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168545,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168546,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168547,100414,RxNorm:3638,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168548,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168675,100419,RxNorm:194000,"{'DPYD': 'Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity'}","Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",Strong,{'DPYD': 'Normal Metabolizer'},{'DPYD': '2.0'},{},{'DPYD': '2.0'},general,n/a,1,False,False,False
4168550,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168551,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168552,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168553,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168554,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168555,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168556,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168557,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168558,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168559,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168560,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168561,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168562,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168563,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168564,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168565,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168566,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168567,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168568,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168569,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168570,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168571,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168572,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168573,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168574,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168676,100419,RxNorm:194000,{'DPYD': 'Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs'},Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).,Moderate,{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.5'},{},{'DPYD': '1.5'},general,Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.,1,False,False,False
4168575,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168576,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168577,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168578,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168579,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168580,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168581,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168582,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168583,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168584,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168585,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168586,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168587,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168588,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168589,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168590,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168591,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168592,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168593,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168594,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168595,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168596,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168597,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168598,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168599,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168600,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168601,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168602,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168603,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168604,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168605,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168606,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168607,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168608,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168609,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168610,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168611,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168612,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168613,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168614,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168615,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168616,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168617,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168618,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168619,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168620,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168621,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168622,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168623,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168624,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168625,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168626,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168627,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168628,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168702,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}",Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.,Strong,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168629,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168630,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168631,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168632,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168633,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168634,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168635,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168636,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168637,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168638,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168639,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168640,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168641,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168642,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168643,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168644,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168645,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168646,100414,RxNorm:3638,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168647,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168648,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",No recommendation,Strong,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168649,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168650,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168651,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168652,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168653,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168722,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",Strong,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.,1,False,False,False
4168654,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168655,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168656,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168657,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168658,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168659,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168660,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168661,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168662,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168723,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. SLCO1B1 genotype result is not available.",Strong,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'No Result'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin.,1,False,False,False
4168663,100414,RxNorm:3638,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168664,104245,RxNorm:195085,{'CYP2B6': 'Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers'},Initiate efavirenz with standard dosing (600 mg/day),Strong,{'CYP2B6': 'Ultrarapid Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Ultrarapid Metabolizer'},child >40kg_adult,n/a,1,False,False,False
4168665,104245,RxNorm:195085,{'CYP2B6': 'Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers'},Initiate efavirenz with standard dosing (600 mg/day),Strong,{'CYP2B6': 'Rapid Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Rapid Metabolizer'},child >40kg_adult,n/a,1,False,False,False
4168666,104245,RxNorm:195085,{'CYP2B6': 'Normal efavirenz metabolism'},Initiate efavirenz with standard dosing (600 mg/day),Strong,{'CYP2B6': 'Normal Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Normal Metabolizer'},child >40kg_adult,"The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype (PMID 24522178).",1,False,False,False
4168667,104245,RxNorm:195085,{'CYP2B6': 'Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events'},Consider initiating efavirenz with decreased dose of 400 mg/day,Moderate,{'CYP2B6': 'Intermediate Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Intermediate Metabolizer'},child >40kg_adult,"If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.",1,False,False,False
4168668,104245,RxNorm:195085,{'CYP2B6': 'Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation'},Consider initiating efavirenz with decreased dose of 400 or 200 mg/day,Moderate,{'CYP2B6': 'Poor Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Poor Metabolizer'},child >40kg_adult,"If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.",1,False,False,False
4168669,104245,RxNorm:195085,{'CYP2B6': 'n/a'},No recommendation,No Recommendation,{'CYP2B6': 'Indeterminate'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Indeterminate'},child >40kg_adult,n/a,1,False,False,False
4168670,100419,RxNorm:4492,"{'DPYD': 'Normal DPD activity and ""normal"" risk for fluoropyrimidine toxicity'}","Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",Strong,{'DPYD': 'Normal Metabolizer'},{'DPYD': '2.0'},{},{'DPYD': '2.0'},general,n/a,1,False,False,False
4168671,100419,RxNorm:4492,{'DPYD': 'Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs'},Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).,Moderate,{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.5'},{},{'DPYD': '1.5'},general,Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.,1,False,False,False
4168672,100419,RxNorm:4492,{'DPYD': 'Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs'},Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.,Strong,{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.0'},{},{'DPYD': '1.0'},general,Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.,1,False,False,False
4168673,100419,RxNorm:4492,{'DPYD': 'Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.'},"Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",Strong,{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.5'},{},{'DPYD': '0.5'},general,"If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance. Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue therapy if the drug level is too high.",1,False,False,False
4168674,100419,RxNorm:4492,{'DPYD': 'Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.'},Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.,Strong,{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.0'},{},{'DPYD': '0.0'},general,n/a,1,False,False,False
4168677,100419,RxNorm:194000,{'DPYD': 'Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs'},Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.,Strong,{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.0'},{},{'DPYD': '1.0'},general,Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.,1,False,False,False
4168678,100419,RxNorm:194000,{'DPYD': 'Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.'},"Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",Strong,{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.5'},{},{'DPYD': '0.5'},general,"If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance. Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue therapy if the drug level is too high.",1,False,False,False
4168679,100419,RxNorm:194000,{'DPYD': 'Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.'},Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.,Strong,{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.0'},{},{'DPYD': '0.0'},general,n/a,1,False,False,False
4168680,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168681,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168682,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168683,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168684,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168742,100413,RxNorm:42355,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4168743,100413,RxNorm:42355,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4168685,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168686,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168687,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168688,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168689,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168690,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168691,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168692,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}","Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day.",Moderate,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168693,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168694,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168695,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168696,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168697,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168698,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168699,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168700,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}",Prescribe an alternative statin depending on the desired potency. (see Table 2 and Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Optional,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168701,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}",Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines.,Strong,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168703,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.,Moderate,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168704,100426,RxNorm:41127,"{'CYP2C9': 'Normal exposure.', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}",Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.,Moderate,"{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': '2.0'},{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168705,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168706,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168707,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.",Strong,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168708,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",n/a,n/a,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Indeterminate'}",general,n/a,1,False,False,False
4168709,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",n/a,n/a,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'No Result'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'No Result'}",general,n/a,1,False,False,False
4168710,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 phenotype could not be assigned based on genotyping.",Strong,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168711,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}","Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': 'n/a'},{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168712,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168744,100413,RxNorm:42355,{'CYP2D6': 'Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4168713,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168714,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'No Result'}",{'CYP2C9': '1.0'},{},"{'CYP2C9': '1.0', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168715,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",Moderate,"{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'No Result'}",{'CYP2C9': '1.5'},{},"{'CYP2C9': '1.5', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168716,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.",Moderate,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Decreased Function'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168717,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.",Strong,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Increased Function'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168718,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",n/a,n/a,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Indeterminate'}",general,n/a,1,False,False,False
4168719,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. CYP2C9 genotype result is not available.",Strong,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Normal Function'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168720,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal and decreased function; Typical myopathy risk with doses less ≤40 mg.'}","Based on SLCO1B1 status, prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If patient is tolerating 40mg per day but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy with fluvastatin especially with doses >40mg per day. CYP2C9 genotype result is not available.",Moderate,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Poor Function'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168721,100426,RxNorm:41127,"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased fluvastatin exposure as compared to normal function; Typical myopathy risk with ≤40 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.",Moderate,"{'CYP2C9': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",{'CYP2C9': 'No Result'},{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168745,100413,RxNorm:42355,{'CYP2D6': 'Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4168724,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168725,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Indeterminate'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168726,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'No Result'}",{'CYP2C9': '0.0'},{},"{'CYP2C9': '0.0', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168727,100426,RxNorm:41127,"{'CYP2C9': 'Increased fluvastatin exposure as compared to normal and intermediate metabolizer which may translate to increased myopathy risk.', 'SLCO1B1': 'n/a'}","Based on CYP2C9 status, prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., fluvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",Moderate,"{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'No Result'}",{'CYP2C9': '0.5'},{},"{'CYP2C9': '0.5', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168728,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4168729,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4168730,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4168731,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4168732,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4168733,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4168734,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4168735,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4168736,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4168737,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4168738,100413,RxNorm:42355,{'CYP2D6': 'No data available for CYP2D6 ultrarapid metabolizers'},No recommendation due to lack of evidence,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4168739,100413,RxNorm:42355,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4168740,100413,RxNorm:42355,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4168741,100413,RxNorm:42355,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4168748,100413,RxNorm:42355,{'CYP2D6': 'Greatly reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Consider a 25-50% lower starting dose and slower titration schedule as compared to normal metabolizers or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.,Optional,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4168749,100413,RxNorm:42355,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4168750,100416,RxNorm:5489,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4168751,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4168752,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4168753,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4168754,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4168755,100416,RxNorm:5489,{'CYP2D6': 'Normal hydromorphone formation'},Use hydrocodone label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4168756,100416,RxNorm:5489,{'CYP2D6': 'Normal hydromorphone formation'},Use hydrocodone label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4168757,100416,RxNorm:5489,{'CYP2D6': 'Normal hydromorphone formation'},Use hydrocodone label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4168758,100416,RxNorm:5489,{'CYP2D6': 'Normal hydromorphone formation'},Use hydrocodone label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4168759,100416,RxNorm:5489,{'CYP2D6': 'Normal hydromorphone formation'},Use hydrocodone label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4168760,100416,RxNorm:5489,"{'CYP2D6': 'Decreased metabolism of hydrocodone to active metabolite, hydromorphone, but there is insufficient evidence to determine if these effects on pharmacokinetics translate into decreased analgesia or side effects.'}","Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.",Optional,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,n/a,1,False,False,False
4168761,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4168762,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4168763,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4168764,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4168765,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4168766,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4168767,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4168768,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4168769,100416,RxNorm:5489,{'CYP2D6': 'Minimal evidence for pharmacokinetic or clinical effect.'},No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4168772,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168773,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168774,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168775,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168776,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168777,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169154,2405438,RxNorm:8120,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4168778,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168779,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168780,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168781,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168782,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168783,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168784,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168785,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168786,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169334,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4168787,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168788,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168789,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168790,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168791,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168792,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168793,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168794,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168795,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168796,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168797,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168798,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168799,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168800,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168801,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168802,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168803,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168804,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168805,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168806,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168807,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168808,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168809,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168810,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168811,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168812,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168813,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168814,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168815,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168816,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",No recommendation,Strong,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4168817,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168818,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168819,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168820,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168821,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168822,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168823,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168824,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168825,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168826,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168827,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168828,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168919,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168829,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168830,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168831,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168832,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168833,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168834,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168835,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168836,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168837,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168838,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168839,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168840,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168841,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168842,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168843,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168844,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168845,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168897,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168846,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168847,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168848,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168849,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168850,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168851,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168898,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168852,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168853,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168854,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168855,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168856,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168857,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168858,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168859,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168860,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168861,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168862,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168863,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169198,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",PHT naive,n/a,1,False,False,False
4168864,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168865,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168866,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168867,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168868,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168899,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168869,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168870,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168871,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168872,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168873,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168874,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168916,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168875,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168876,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168877,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168878,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168879,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168880,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168881,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168882,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168883,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168884,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4168885,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4168886,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169223,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",PHT use >3mos,n/a,1,False,False,False
4168887,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168888,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168889,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168890,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168891,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168892,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168893,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168894,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168895,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168896,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168917,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168900,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168901,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168902,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168903,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168904,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168905,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168906,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168907,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168908,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168909,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168918,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168910,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168911,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168912,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168913,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168914,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168915,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169383,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4168920,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168921,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168922,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168923,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168924,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168925,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168926,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168927,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168928,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168929,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168930,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168931,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4168932,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168933,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168934,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168968,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168935,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168936,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168937,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168938,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168939,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168980,100426,RxNorm:6472,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Increased Function'},{},{},{'SLCO1B1': 'Increased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4168940,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168941,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168942,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168943,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168944,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168945,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169407,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4168946,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168947,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168948,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168949,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168950,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168951,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168952,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168953,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4168954,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168955,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168956,100414,RxNorm:5691,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168957,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168958,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168959,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168960,100414,RxNorm:5691,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4168961,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168962,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168963,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168964,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168965,100414,RxNorm:5691,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4168966,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168967,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168969,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168970,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168971,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168972,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168973,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168974,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168975,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168976,100414,RxNorm:5691,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168977,100414,RxNorm:5691,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4168978,100409,RxNorm:1243041,{'CFTR': 'An individual diagnosed with cystic fibrosis (CF) and negative for a CFTR variant listed in the FDA-approved drug label as being responsive to ivacaftor.'},Ivacaftor is not recommended,Moderate,{'CFTR': 'ivacaftor non-responsive in CF patients'},{'CFTR': 'n/a'},{},{'CFTR': 'ivacaftor non-responsive in CF patients'},general,n/a,1,False,False,False
4168979,100409,RxNorm:1243041,{'CFTR': 'An individual diagnosed with cystic fibrosis (CF) and CFTR variants listed in the FDA-approved drug label as being responsive to ivacaftor'},Use ivacaftor according to the product label,Moderate,{'CFTR': 'ivacaftor responsive in CF patients'},{'CFTR': 'n/a'},{},{'CFTR': 'ivacaftor responsive in CF patients'},general,n/a,1,False,False,False
4168982,100426,RxNorm:6472,{'SLCO1B1': 'Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.",Moderate,{'SLCO1B1': 'Possible Decreased Function'},{},{},{'SLCO1B1': 'Possible Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168983,100426,RxNorm:6472,{'SLCO1B1': 'Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.",Moderate,{'SLCO1B1': 'Decreased Function'},{},{},{'SLCO1B1': 'Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168984,100426,RxNorm:6472,{'SLCO1B1': 'Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk'},Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Moderate,{'SLCO1B1': 'Poor Function'},{},{},{'SLCO1B1': 'Poor Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4168985,100426,RxNorm:6472,{'SLCO1B1': 'n/a'},No recommendation,No Recommendation,{'SLCO1B1': 'Indeterminate'},{},{},{'SLCO1B1': 'Indeterminate'},general,n/a,1,False,False,False
4168986,110058,RxNorm:41493,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4168987,110058,RxNorm:41493,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.,1,False,False,False
4168988,110058,RxNorm:41493,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,"IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4168989,110058,RxNorm:41493,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,n/a,1,False,False,False
4168990,110058,RxNorm:41493,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,n/a,1,False,False,False
4168991,110058,RxNorm:41493,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4168992,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4169039,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4168993,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168994,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168995,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168996,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4168997,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4168998,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4169040,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4168999,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169000,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169001,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169002,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169003,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169041,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4169004,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169005,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169006,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169007,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169008,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169408,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4169009,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169010,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169011,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169012,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169013,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169014,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169409,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4169015,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169016,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169017,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169018,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169019,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169020,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169332,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4169021,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169022,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169023,100428,RxNorm:103,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169024,100428,RxNorm:103,"{'TPMT': ""Lower concentrations of TGN metabolites, higher MeTIMP, this is the 'normal' pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression."", 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169025,100428,RxNorm:103,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169410,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4169026,100428,RxNorm:103,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169027,2405438,RxNorm:6878,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid ased on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169028,2405438,RxNorm:6878,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,,1,False,False,False
4169029,2405438,RxNorm:6878,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",1,False,False,False
4169030,2405438,RxNorm:6878,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.",1,False,False,False
4169031,2405438,RxNorm:6878,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169032,2405438,RxNorm:7454,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169033,2405438,RxNorm:7454,{'G6PD': 'Medium risk of acute hemolytic anemia'},Use at standard doses with caution and with close monitoring for anemia,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Close monitoring may be more important at higher or more chronic dosage schedules, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169034,2405438,RxNorm:7454,{'G6PD': 'High risk of acute of acute exacerbation of chronic hemolysis'},Avoid,Moderate,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype to rate as ""strong,"" but all medium risk drugs should be avoided in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.",1,False,False,False
4169035,2405438,RxNorm:7454,{'G6PD': 'Variable risk of acute hemolytic anemia'},"If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.",1,False,False,False
4169036,2405438,RxNorm:7454,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169037,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4169038,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4169155,2405438,RxNorm:8120,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169042,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4169043,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4169044,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4169045,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4169046,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4169047,100414,RxNorm:7531,{'CYP2D6': 'Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.'},"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4169048,100414,RxNorm:7531,{'CYP2D6': 'Normal metabolism of tricyclic antidepressants'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169049,100414,RxNorm:7531,{'CYP2D6': 'Normal metabolism of tricyclic antidepressants'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169050,100414,RxNorm:7531,{'CYP2D6': 'Normal metabolism of tricyclic antidepressants'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169051,100414,RxNorm:7531,{'CYP2D6': 'Normal metabolism of tricyclic antidepressants'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169052,100414,RxNorm:7531,{'CYP2D6': 'Normal metabolism of tricyclic antidepressants'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169062,110076,RxNorm:7646,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169053,100414,RxNorm:7531,{'CYP2D6': 'Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169054,100414,RxNorm:7531,{'CYP2D6': 'Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169055,100414,RxNorm:7531,{'CYP2D6': 'Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169056,100414,RxNorm:7531,{'CYP2D6': 'Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169057,100414,RxNorm:7531,{'CYP2D6': 'Greatly reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.'},"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",Strong,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169058,100414,RxNorm:7531,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,"Because CYP2D6 phenotype could not be assigned based on genotyping performed, therapuetic monitoring should be considered. If therapuetic monitoring cannot be performed, monitor closely for toxicity and/or efficacy.",1,False,False,False
4169059,110076,RxNorm:7646,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,n/a,1,False,False,False
4169060,110076,RxNorm:7646,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,n/a,1,False,False,False
4169061,110076,RxNorm:7646,{'CYP2C19': 'Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4169063,110076,RxNorm:7646,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,n/a,1,False,False,False
4169064,110076,RxNorm:7646,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169065,110076,RxNorm:7646,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,n/a,1,False,False,False
4169066,110076,RxNorm:7646,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4169067,110076,RxNorm:17128,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,n/a,1,False,False,False
4169068,110076,RxNorm:17128,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,n/a,1,False,False,False
4169069,110076,RxNorm:17128,{'CYP2C19': 'Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4169070,110076,RxNorm:17128,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169071,110076,RxNorm:17128,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},general,n/a,1,False,False,False
4169072,110076,RxNorm:17128,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169073,110076,RxNorm:17128,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,n/a,1,False,False,False
4169074,110076,RxNorm:17128,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4169075,110076,RxNorm:40790,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},general,n/a,1,False,False,False
4169076,110076,RxNorm:40790,{'CYP2C19': 'Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},general,n/a,1,False,False,False
4169077,110076,RxNorm:40790,{'CYP2C19': 'Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs'},"Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.
Monitor for efficacy.",Moderate,{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},general,n/a,1,False,False,False
4169078,110076,RxNorm:40790,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169080,110076,RxNorm:40790,{'CYP2C19': 'Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},general,"The strength of recommendation for ""likely"" phenotypes are the same as their respective confirmed phenotypes. ""Likely"" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding ""likely"" phenotype.",1,False,False,False
4169081,110076,RxNorm:40790,{'CYP2C19': 'Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity'},"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Moderate,{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},general,n/a,1,False,False,False
4169082,110076,RxNorm:40790,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},general,n/a,1,False,False,False
4169083,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169084,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169085,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169086,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169087,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169088,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169089,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169090,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169091,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169092,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169093,100417,RxNorm:26225,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169094,100417,RxNorm:26225,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169095,100417,RxNorm:26225,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169096,100417,RxNorm:26225,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169097,100417,RxNorm:26225,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169098,100417,RxNorm:26225,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169099,100417,RxNorm:26225,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169100,100417,RxNorm:26225,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169101,100417,RxNorm:26225,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169102,100417,RxNorm:26225,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169103,100417,RxNorm:26225,{'CYP2D6': 'Very limited data available for CYP2D6 poor metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169104,100417,RxNorm:26225,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169156,2405438,RxNorm:8120,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169105,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169106,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169107,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169108,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169109,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169110,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169111,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169112,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169113,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169114,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169115,100417,RxNorm:27392,{'CYP2D6': 'Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).'},"Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",1,False,False,False
4169116,100417,RxNorm:27392,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169117,100417,RxNorm:27392,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169118,100417,RxNorm:27392,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169119,100417,RxNorm:27392,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169120,100417,RxNorm:27392,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169121,100417,RxNorm:27392,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169122,100417,RxNorm:27392,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169123,100417,RxNorm:27392,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169124,100417,RxNorm:27392,{'CYP2D6': 'Very limited data available for CYP2D6 intermediate metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169125,100417,RxNorm:27392,{'CYP2D6': 'Very limited data available for CYP2D6 poor metabolizers'},Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.,No Recommendation,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",1,False,False,False
4169126,100417,RxNorm:27392,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169127,100423,RxNorm:32624,{'HLA-B': 'Normal risk of oxcarbazepine-induced SJS/TEN'},Use oxcarbazepine per standard dosing guidelines.,Strong,{},{},{'HLA-B': 'HLA-B*15:02 negative'},{'HLA-B': '*15:02 negative'},OXC naive,n/a,1,False,False,False
4169128,100423,RxNorm:32624,{'HLA-B': 'Greater risk of oxcarbazepine-induced SJS/TEN'},"If patient is oxcarbazepine-naïve, do not use oxcarbazepine.",Strong,{},{},{'HLA-B': 'HLA-B*15:02 positive'},{'HLA-B': '*15:02 positive'},OXC naive,"Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",1,False,False,False
4169129,100423,RxNorm:32624,{'HLA-B': 'Normal risk of oxcarbazepine-induced SJS/TEN'},Use oxcarbazepine per standard dosing guidelines.,Strong,{},{'HLA-B': 'n/a'},{'HLA-B': 'HLA-B*15:02 negative'},{'HLA-B': '*15:02 negative'},OXC use >3 mos,n/a,1,False,False,False
4169130,100423,RxNorm:32624,{'HLA-B': 'Greater risk of oxcarbazepine-induced SJS/TEN'},"The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",Optional,{},{'HLA-B': 'n/a'},{'HLA-B': 'HLA-B*15:02 positive'},{'HLA-B': '*15:02 positive'},OXC use >3 mos,"Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",1,False,False,False
4169131,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169132,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169133,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169134,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169135,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169136,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169137,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169138,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169139,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169140,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169157,2405438,RxNorm:8120,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169141,100413,RxNorm:32937,"{'CYP2D6': 'Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear.'}",Select alternative drug not predominantly metabolized by CYP2D6.,Moderate,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169142,100413,RxNorm:32937,{'CYP2D6': 'Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4169143,100413,RxNorm:32937,{'CYP2D6': 'Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4169144,100413,RxNorm:32937,{'CYP2D6': 'Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4169145,100413,RxNorm:32937,{'CYP2D6': 'Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4169146,100413,RxNorm:32937,{'CYP2D6': 'Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Initiate therapy with recommended starting dose,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4169147,100413,RxNorm:32937,{'CYP2D6': 'Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169148,100413,RxNorm:32937,{'CYP2D6': 'Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169149,100413,RxNorm:32937,{'CYP2D6': 'Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169150,100413,RxNorm:32937,{'CYP2D6': 'Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations.'},Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.,Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169151,100413,RxNorm:32937,{'CYP2D6': 'Greatly reduced metabolism when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects. The impact of paroxetine-associated autoinhibition of CYP2D6 is minimal in poor metabolizers.'},"Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.",Moderate,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169152,100413,RxNorm:32937,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169153,2405438,RxNorm:8120,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169160,2405438,RxNorm:9071,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169161,2405438,RxNorm:9071,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169162,2405438,RxNorm:9071,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169163,2405438,RxNorm:10171,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169164,2405438,RxNorm:10171,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169165,2405438,RxNorm:10171,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169166,2405438,RxNorm:10171,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169167,2405438,RxNorm:10171,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169168,2405438,RxNorm:10178,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169169,2405438,RxNorm:10178,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169170,2405438,RxNorm:10178,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169171,2405438,RxNorm:10178,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169172,2405438,RxNorm:10178,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169173,2405438,RxNorm:10831,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169174,2405438,RxNorm:10831,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169175,2405438,RxNorm:10831,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169176,2405438,RxNorm:10831,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169178,2405438,RxNorm:10184,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169180,2405438,RxNorm:10184,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169181,2405438,RxNorm:10184,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169182,2405438,RxNorm:10184,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169183,2405438,RxNorm:9524,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169184,2405438,RxNorm:9524,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169185,2405438,RxNorm:9524,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169186,2405438,RxNorm:9524,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169187,2405438,RxNorm:9524,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169188,2405438,RxNorm:10207,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169189,2405438,RxNorm:10207,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169190,2405438,RxNorm:10207,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169191,2405438,RxNorm:10207,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169192,2405438,RxNorm:10207,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169193,2405438,RxNorm:10635,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169194,2405438,RxNorm:10635,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Optional,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,"Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.",1,False,False,False
4169195,2405438,RxNorm:10635,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},"Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended",Optional,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for for acute exacerbation of chronic hemolysis.",1,False,False,False
4169196,2405438,RxNorm:10635,{'G6PD': 'Low-to-no risk of acute hemolytic anemia'},No reason to avoid based on G6PD status at standard doses,Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.",1,False,False,False
4169411,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4169199,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",PHT naive,n/a,1,False,False,False
4169200,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",PHT naive,n/a,1,False,False,False
4169201,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",PHT naive,n/a,1,False,False,False
4169202,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",PHT naive,n/a,1,False,False,False
4169203,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",PHT naive,n/a,1,False,False,False
4169204,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Normal phenytoin metabolism'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169205,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169206,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169207,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169208,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169209,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169210,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '2.0'}",PHT naive,n/a,1,False,False,False
4169211,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.5'}",PHT naive,n/a,1,False,False,False
4169212,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.0'}",PHT naive,n/a,1,False,False,False
4169213,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.5'}",PHT naive,n/a,1,False,False,False
4169214,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.0'}",PHT naive,n/a,1,False,False,False
4169215,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': 'n/a'}",PHT naive,n/a,1,False,False,False
4169216,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",PHT naive,n/a,1,False,False,False
4169217,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169218,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",PHT use >3mos,n/a,1,False,False,False
4169219,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",PHT use >3mos,n/a,1,False,False,False
4169220,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",PHT use >3mos,n/a,1,False,False,False
4169221,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",PHT use >3mos,n/a,1,False,False,False
4169222,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",PHT use >3mos,n/a,1,False,False,False
4169224,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Normal phenytoin metabolism'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169225,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169226,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169227,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169228,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169229,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169230,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '2.0'}",PHT use >3mos,n/a,1,False,False,False
4169231,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.5'}",PHT use >3mos,n/a,1,False,False,False
4169232,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.0'}",PHT use >3mos,n/a,1,False,False,False
4169233,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.5'}",PHT use >3mos,n/a,1,False,False,False
4169234,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.0'}",PHT use >3mos,n/a,1,False,False,False
4169235,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': 'n/a'}",PHT use >3mos,n/a,1,False,False,False
4169236,100412,RxNorm:8183,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",PHT use >3mos,n/a,1,False,False,False
4169237,100412,RxNorm:8183,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169238,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",PHT naive,n/a,1,False,False,False
4169239,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",PHT naive,n/a,1,False,False,False
4169240,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",PHT naive,n/a,1,False,False,False
4169241,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",PHT naive,n/a,1,False,False,False
4169242,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",PHT naive,n/a,1,False,False,False
4169243,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",PHT naive,n/a,1,False,False,False
4169244,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Normal phenytoin metabolism'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169245,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169412,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4169246,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169247,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169248,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169249,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169250,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '2.0'}",PHT naive,n/a,1,False,False,False
4169251,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.5'}",PHT naive,n/a,1,False,False,False
4169252,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.0'}",PHT naive,n/a,1,False,False,False
4169253,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.5'}",PHT naive,n/a,1,False,False,False
4169254,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.0'}",PHT naive,n/a,1,False,False,False
4169255,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': 'n/a'}",PHT naive,n/a,1,False,False,False
4169256,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",PHT naive,n/a,1,False,False,False
4169257,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",PHT naive,"Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",1,False,False,False
4169258,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",PHT use >3mos,n/a,1,False,False,False
4169259,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",PHT use >3mos,n/a,1,False,False,False
4169260,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",PHT use >3mos,n/a,1,False,False,False
4169261,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",PHT use >3mos,n/a,1,False,False,False
4169262,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",PHT use >3mos,n/a,1,False,False,False
4169263,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",PHT use >3mos,n/a,1,False,False,False
4169264,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Normal phenytoin metabolism'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169265,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169266,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169267,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169333,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4169268,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169269,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169270,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Normal phenytoin metabolism'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '2.0'}",PHT use >3mos,n/a,1,False,False,False
4169271,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.5'}",PHT use >3mos,n/a,1,False,False,False
4169272,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '1.0'}",PHT use >3mos,n/a,1,False,False,False
4169273,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.5'}",PHT use >3mos,n/a,1,False,False,False
4169274,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities.'}","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': '0.0'}",PHT use >3mos,n/a,1,False,False,False
4169275,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}",No recommendation,n/a,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No HLA-B Result'},"{'HLA-B': 'No Result', 'CYP2C9': 'n/a'}",PHT use >3mos,n/a,1,False,False,False
4169276,100412,RxNorm:72236,"{'HLA-B': 'n/a', 'CYP2C9': 'n/a'}","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",Strong,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",PHT use >3mos,n/a,1,False,False,False
4169277,100412,RxNorm:72236,"{'HLA-B': 'Increased risk of phenytoin-induced SJS/TEN', 'CYP2C9': 'n/a'}","If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",Optional,{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'HLA-B*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",PHT use >3mos,Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.,1,False,False,False
4169278,110058,RxNorm:8356,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4169279,110058,RxNorm:8356,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.,1,False,False,False
4169280,110058,RxNorm:8356,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169281,110058,RxNorm:8356,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169282,110058,RxNorm:8356,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Moderate,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169283,110058,RxNorm:8356,{'CYP2C9': 'n/a'},No recommendation,No Recommendation,{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},general,n/a,1,False,False,False
4169284,100426,RxNorm:861634,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Increased Function'},{},{},{'SLCO1B1': 'Increased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169285,100426,RxNorm:861634,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Normal Function'},{},{},{'SLCO1B1': 'Normal Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169286,100426,RxNorm:861634,{'SLCO1B1': 'Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,{'SLCO1B1': 'Possible Decreased Function'},{},{},{'SLCO1B1': 'Possible Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169287,100426,RxNorm:861634,{'SLCO1B1': 'Increased pitavastatin exposure as compared to normal function which may translate to increased myopathy risk'},"Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,{'SLCO1B1': 'Decreased Function'},{},{},{'SLCO1B1': 'Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169288,100426,RxNorm:861634,{'SLCO1B1': 'Increased pitavastatin exposure as compared to normal and decreased function which may translate to increased myopathy risk.'},"Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If dose >1mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy)(PMID: 30423391).",Moderate,{'SLCO1B1': 'Poor Function'},{},{},{'SLCO1B1': 'Poor Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169289,100426,RxNorm:861634,{'SLCO1B1': 'n/a'},No recommendation,No Recommendation,{'SLCO1B1': 'Indeterminate'},{},{},{'SLCO1B1': 'Indeterminate'},general,n/a,1,False,False,False
4169290,100426,RxNorm:42463,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Increased Function'},{},{},{'SLCO1B1': 'Increased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169291,100426,RxNorm:42463,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Normal Function'},{},{},{'SLCO1B1': 'Normal Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169413,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4169292,100426,RxNorm:42463,{'SLCO1B1': 'Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.'},Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.,Moderate,{'SLCO1B1': 'Possible Decreased Function'},{},{},{'SLCO1B1': 'Possible Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169293,100426,RxNorm:42463,{'SLCO1B1': 'Increased pravastatin exposure as compared to normal function; Typical myopathy risk with doses ≤40 mg.'},Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.,Moderate,{'SLCO1B1': 'Decreased Function'},{},{},{'SLCO1B1': 'Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169294,100426,RxNorm:42463,{'SLCO1B1': 'Increased pravastatin statin exposure as compared to normal and decreased function; Typical myopathy risk with doses ≤40 mg.'},"Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If patient is tolerating 40mg dose but higher potency is needed, a higher dose (>40mg) or an alternative statin (see Figure 1 of of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pravastatin plus non-statin guideline directed medical therapy)(PMID: 30423391) could be considered. Prescriber should be aware of possible increased risk for myopathy especially with pravastatin doses >40mg.",Moderate,{'SLCO1B1': 'Poor Function'},{},{},{'SLCO1B1': 'Poor Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169295,100426,RxNorm:42463,{'SLCO1B1': 'n/a'},No recommendation,No Recommendation,{'SLCO1B1': 'Indeterminate'},{},{},{'SLCO1B1': 'Indeterminate'},general,n/a,1,False,False,False
4169296,2405438,RxNorm:8687,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,,1,False,False,False
4169297,2405438,RxNorm:8687,{'G6PD': 'High risk of acute hemolytic anemia with standard (or higher than standard) anti-relapse dosages for Plasmodium vivax or Plasmodium ovale of 0.25-0.5 mg/kg daily for 14 days'},"Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.",Strong,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,Dosing recommendations for primaquine in patients with G6PD deficiency are derived from the malaria treatment guidelines issued by the World Health Organization and the U.S. Centers for Disease Control and Prevention.,1,False,False,False
4169298,2405438,RxNorm:8687,{'G6PD': 'High risk of acute of acute exacerbation of chronic hemolysis'},Avoid primaquine,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,The strength of evidence among patients with the G6PD Deficient phenotype provides strong rationale to also avoid primaquine in the setting of the more severe G6PD Deficient with CNSHA phenotype.,1,False,False,False
4169299,2405438,RxNorm:8687,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one nondeficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to guide treatment in such cases.",1,False,False,False
4169300,2405438,RxNorm:8687,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169301,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}","Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Decreased Function'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169302,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}","Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Possible Decreased Function'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169303,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.'}","Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >10mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Poor Function'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169304,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.'}","Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose > 20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Poor Function'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169305,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}","Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Increased Function'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169306,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}","Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Optional,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Normal Function'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169307,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.'}","Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).",Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Poor Function'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169308,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.,Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Increased Function'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169309,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.,Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Increased Function'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.,1,False,False,False
4169310,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.,Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Normal Function'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169311,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.,Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Normal Function'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.,1,False,False,False
4169312,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Decreased Function'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169313,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Possible Decreased Function'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169314,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Decreased Function'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169315,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}",Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.,Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Possible Decreased Function'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169316,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.",Strong,"{'ABCG2': 'No Result', 'SLCO1B1': 'Decreased Function'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169317,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.",Strong,"{'ABCG2': 'No Result', 'SLCO1B1': 'Increased Function'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Increased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169318,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Indeterminate'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169319,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",n/a,n/a,"{'ABCG2': 'No Result', 'SLCO1B1': 'Indeterminate'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Indeterminate'}",general,n/a,1,False,False,False
4169320,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 phenotype could not be assigned based on genotyping.",Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Indeterminate'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.,1,False,False,False
4169330,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher
maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",Optional,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4169321,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 phenotype could not be assigned based on genotyping.",Moderate,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Indeterminate'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Indeterminate'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169322,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure as compared to normal function; unknown risk for myopathy; increased lipid lowering effects', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.",Moderate,"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'No Result'}",{},{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169323,100426,RxNorm:301542,"{'ABCG2': 'Typical myopathy risk and rosuvastatin exposure', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. SLCO1B1 genotype result is not available.",Strong,"{'ABCG2': 'Normal Function', 'SLCO1B1': 'No Result'}",{},{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin.,1,False,False,False
4169324,100426,RxNorm:301542,"{'ABCG2': 'Increased rosuvastatin exposure compared to normal and decreased function; unknown myopathy risk; increased lipid-lowering effects', 'SLCO1B1': 'n/a'}","Based on ABCG2 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e., rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). SLCO1B1 genotype result is not available.",Moderate,"{'ABCG2': 'Poor Function', 'SLCO1B1': 'No Result'}",{},{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'No Result'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating rosuvastatin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169325,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'Typical myopathy risk and statin exposure'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses based on disease-specific guidelines. ABCG2 genotype result is not available.",Strong,"{'ABCG2': 'No Result', 'SLCO1B1': 'Normal Function'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Normal Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169326,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function and decreased function; Typical myopathy risk with doses ≤20 mg.'}","Based on SLCO1B1 status, prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391). ABCG2 genotype result is not available.",Moderate,"{'ABCG2': 'No Result', 'SLCO1B1': 'Poor Function'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Poor Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169327,100426,RxNorm:301542,"{'ABCG2': 'n/a', 'SLCO1B1': 'Increased rosuvastatin exposure as compared to normal function; Typical myopathy risk with doses ≤20 mg.'}","Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg. ABCG2 genotype result is not available.",Strong,"{'ABCG2': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",{},{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and Asian ancestry should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169328,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169329,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher
maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",Optional,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4169331,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,n/a,1,False,False,False
4169335,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169336,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher
maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",Optional,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169337,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher
maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6.",Optional,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169338,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169339,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169340,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169341,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}",general,n/a,1,False,False,False
4169342,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose,Strong,"{'CYP2B6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169343,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169344,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169345,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169346,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169347,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Normal metabolism'}","Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169348,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Normal metabolism'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169349,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Moderate,"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169350,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169351,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169352,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169353,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Optional,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169354,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers",Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169355,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169356,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.,Moderate,"{'CYP2B6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169357,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169358,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169359,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169360,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers.,Optional,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169414,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4169361,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers",Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169362,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers.'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169363,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169364,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169365,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169366,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169367,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169368,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}",Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.,Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169369,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}",general,n/a,1,False,False,False
4169370,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169371,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169372,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Optional,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169373,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169374,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169375,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}",Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6.,Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169376,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'}","Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.",Moderate,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}",general,n/a,1,False,False,False
4169377,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2B6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,"CYP2B6 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169378,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169379,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169380,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169381,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose.,Moderate,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169382,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'n/a'}","Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169384,100413,RxNorm:36437,"{'CYP2B6': 'Increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Moderate,"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}",general,"CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169385,100413,RxNorm:36437,"{'CYP2B6': 'Small increase in metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'No Result'}",general,"CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169386,100413,RxNorm:36437,"{'CYP2B6': 'Normal metabolism of sertraline to less active compounds.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}",general,"CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169387,100413,RxNorm:36437,"{'CYP2B6': 'Reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers.', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.,Optional,"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}",general,"CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169388,100413,RxNorm:36437,"{'CYP2B6': 'Greatly reduced metabolism of sertraline to less active compounds when compared to CYP2B6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.', 'CYP2C19': 'n/a'}","Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.",Optional,"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}",general,"CYPC19 metabolizer status, drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be also considered.",1,False,False,False
4169389,100413,RxNorm:36437,"{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,No Recommendation,"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169390,100426,RxNorm:36567,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Increased Function'},{},{},{'SLCO1B1': 'Increased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169391,100426,RxNorm:36567,{'SLCO1B1': 'Typical myopathy risk and statin exposure'},Prescribe desired starting dose and adjust doses based on disease-specific guidelines.,Strong,{'SLCO1B1': 'Normal Function'},{},{},{'SLCO1B1': 'Normal Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.,1,False,False,False
4169392,100426,RxNorm:36567,{'SLCO1B1': 'Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy'},"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.",Strong,{'SLCO1B1': 'Possible Decreased Function'},{},{},{'SLCO1B1': 'Possible Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169393,100426,RxNorm:36567,{'SLCO1B1': 'Increased simvastatin acid exposure as compared to normal function; increased risk of myopathy'},"Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.",Strong,{'SLCO1B1': 'Decreased Function'},{},{},{'SLCO1B1': 'Decreased Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169394,100426,RxNorm:36567,{'SLCO1B1': 'Increased simvastatin acid exposure compared to normal and decreased function; highly increased myopathy risk'},Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).,Strong,{'SLCO1B1': 'Poor Function'},{},{},{'SLCO1B1': 'Poor Function'},general,The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.,1,False,False,False
4169395,100426,RxNorm:36567,{'SLCO1B1': 'n/a'},No recommendation,No Recommendation,{'SLCO1B1': 'Indeterminate'},{},{},{'SLCO1B1': 'Indeterminate'},general,n/a,1,False,False,False
4169415,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4169416,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4169417,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4169396,100418,RxNorm:42316,{'CYP3A5': 'Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.'},Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.,Strong,{'CYP3A5': 'Normal Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Normal Metabolizer'},general,"This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient's genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",1,False,False,False
4169397,100418,RxNorm:42316,{'CYP3A5': 'Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.'},Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.,Strong,{'CYP3A5': 'Possible Intermediate Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Possible Intermediate Metabolizer'},general,"This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient's genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",1,False,False,False
4169398,100418,RxNorm:42316,{'CYP3A5': 'Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.'},Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.,Strong,{'CYP3A5': 'Intermediate Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Intermediate Metabolizer'},general,"This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient's genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",1,False,False,False
4169399,100418,RxNorm:42316,"{'CYP3A5': 'Higher (""normal"") dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations.'}",Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.,Strong,{'CYP3A5': 'Poor Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Poor Metabolizer'},general,"This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient's genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",1,False,False,False
4169400,100418,RxNorm:42316,{'CYP3A5': 'n/a'},No recommendation,No Recommendation,{'CYP3A5': 'Indeterminate'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Indeterminate'},general,n/a,1,False,False,False
4169401,2405438,RxNorm:2054023,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid based on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,Tafenoquine's safety has been established for a G6PD enzyme activity ≥70% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity ≥70%.),1,False,False,False
4169402,2405438,RxNorm:2054023,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Strong,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,,1,False,False,False
4169403,2405438,RxNorm:2054023,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals.",1,False,False,False
4169404,2405438,RxNorm:2054023,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases. Tafenoquine's safety has been established for a G6PD enzyme activity ≥70% of normal. (Inclusion criteria for clinical trials involving tafenoquine included G6PD activity ≥70%.)",1,False,False,False
4169405,2405438,RxNorm:2054023,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,,1,False,False,False
4169406,100415,RxNorm:10324,{'CYP2D6': 'Therapeutic endoxifen concentrations'},Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).,Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4169422,100415,RxNorm:10324,"{'CYP2D6': 'Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.'}","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4169423,100415,RxNorm:10324,"{'CYP2D6': 'Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.'}","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4169424,100415,RxNorm:10324,"{'CYP2D6': 'Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.'}","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4169425,100415,RxNorm:10324,"{'CYP2D6': 'Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.'}","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4169426,100415,RxNorm:10324,"{'CYP2D6': 'Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.'}","Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).",Strong,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,n/a,1,False,False,False
4169427,100415,RxNorm:10324,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169428,110058,RxNorm:37790,{'CYP2C9': 'Normal metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Strong,{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},general,n/a,1,False,False,False
4169429,110058,RxNorm:37790,{'CYP2C9': 'Mildly reduced metabolism'},"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},general,IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.,1,False,False,False
4169430,110058,RxNorm:37790,{'CYP2C9': 'Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Optional,{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169431,110058,RxNorm:37790,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169432,110058,RxNorm:37790,{'CYP2C9': 'Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities'},"Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",Optional,{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},general,"Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",1,False,False,False
4169434,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4169435,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169436,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169437,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169438,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169439,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4169440,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'n/a'}","NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",general,Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.,1,False,False,False
4169478,100416,RxNorm:10689,{'CYP2D6': 'Reduced O-desmethyltramadol (active metabolite) formation'},"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4169441,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169442,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169443,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169444,100428,RxNorm:10485,"{'TPMT': 'n/a', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",1,False,False,False
4169445,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169446,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169447,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169448,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169449,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169450,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169451,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169452,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169453,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169454,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169455,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",1,False,False,False
4169456,100428,RxNorm:10485,"{'TPMT': 'Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression', 'NUDT15': 'n/a'}","Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Moderate,"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169457,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169458,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169479,100416,RxNorm:10689,{'CYP2D6': 'Expected O-desmethyltramadol (active metabolite) formation'},Use tramadol label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4169459,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169460,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169461,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",Moderate,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169462,100428,RxNorm:10485,"{'TPMT': 'Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169463,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169464,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169480,100416,RxNorm:10689,{'CYP2D6': 'Expected O-desmethyltramadol (active metabolite) formation'},Use tramadol label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4169481,100416,RxNorm:10689,{'CYP2D6': 'Expected O-desmethyltramadol (active metabolite) formation'},Use tramadol label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4169482,100416,RxNorm:10689,{'CYP2D6': 'Expected O-desmethyltramadol (active metabolite) formation'},Use tramadol label recommended age- or weight-specific dosing.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4169465,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169466,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169467,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression'}","Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169468,100428,RxNorm:10485,"{'TPMT': 'Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.', 'NUDT15': 'n/a'}","Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",Strong,"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",general,"Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",1,False,False,False
4169469,2405438,RxNorm:10638,{'G6PD': 'Low risk of acute hemolytic anemia'},No reason to avoid ased on G6PD status,Strong,{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},general,Toluidine blue classification strength is based on extrapolation from methylene blue data,1,False,False,False
4169470,2405438,RxNorm:10638,{'G6PD': 'High risk of acute hemolytic anemia'},Avoid use,Moderate,{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},general,Toluidine blue classification strength is based on extrapolation from methylene blue data,1,False,False,False
4169471,2405438,RxNorm:10638,{'G6PD': 'High risk of acute exacerbation of chronic hemolysis'},Avoid use,Strong,{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},general,"Although there are not published data in individuals with the G6PD Deficient with CNSHA phenotype, there is a strong rationale to avoid these drugs based on evidence in G6PD Deficient individuals. Toluidine blue classification strength is based on extrapolation from methylene blue data",1,False,False,False
4169472,2405438,RxNorm:10638,{'G6PD': 'Variable risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},general,"Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases. Toluidine blue classification strength is based on extrapolation from methylene blue data",1,False,False,False
4169473,2405438,RxNorm:10638,{'G6PD': 'Unknown risk of acute hemolytic anemia'},"To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.",Moderate,{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},general,Toluidine blue classification strength is based on extrapolation from methylene blue data,1,False,False,False
4169474,100416,RxNorm:10689,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169475,100416,RxNorm:10689,{'CYP2D6': 'Reduced O-desmethyltramadol (active metabolite) formation'},"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",Optional,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4169484,100416,RxNorm:10689,{'CYP2D6': 'Greatly reduced O-desmethyltramadol (active metabolite) formation leading to diminished analgesia.'},"Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,n/a,1,False,False,False
4169485,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4169486,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4169487,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4169488,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4169489,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4169490,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4169491,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4169492,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4169493,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4169494,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4169495,100416,RxNorm:10689,{'CYP2D6': 'Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity'},"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",Strong,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4169496,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169497,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169757,100413,RxNorm:1455099,{'CYP2D6': 'Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4169498,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169499,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169500,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169501,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169502,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169503,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169541,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169504,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169505,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169506,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169507,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169508,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169509,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169510,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169511,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169512,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169513,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169566,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169514,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169515,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169516,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169517,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169518,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169519,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169575,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169520,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169521,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169522,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169523,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169524,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169576,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169525,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169526,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169527,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169528,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169529,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169598,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169530,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169531,100414,RxNorm:10834,"{'CYP2D6': 'Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}",Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.,Optional,"{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169532,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169533,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169534,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169535,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169536,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169537,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169538,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169539,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169540,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169542,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169543,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169544,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169545,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169546,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169547,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169599,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169548,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169549,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169550,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169551,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169552,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169553,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169600,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169554,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169555,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169556,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169557,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169558,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169559,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169560,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169561,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",No recommendation,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169562,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169563,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169564,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169565,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169567,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169568,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169569,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169570,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169571,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
 for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169572,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169573,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169574,100414,RxNorm:10834,"{'CYP2D6': 'Normal metabolism of TCAs', 'CYP2C19': 'n/a'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169577,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169578,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169579,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169580,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169581,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169582,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169583,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169584,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169585,100414,RxNorm:10834,"{'CYP2D6': 'Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",1,False,False,False
4169586,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169587,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169588,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169589,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169590,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169591,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169592,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169593,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169594,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169595,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169596,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169597,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169601,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169602,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169603,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169604,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169605,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169606,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169607,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Normal metabolism of tertiary amines'}","Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169608,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169609,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169758,100413,RxNorm:1455099,{'CYP2D6': 'Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4169610,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169611,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169612,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169613,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169614,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169615,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169616,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169617,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169618,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169619,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169620,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169621,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169622,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169623,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169624,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169625,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169626,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169627,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169628,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169629,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169630,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169631,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169632,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169633,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169634,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169635,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169636,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169637,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169638,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169639,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169640,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",1,False,False,False
4169641,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169642,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169643,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169644,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169645,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169646,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169647,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169706,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,n/a,1,False,False,False
4169648,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169649,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169650,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169651,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169652,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169653,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169654,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169655,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169731,100410,RxNorm:121243,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},pediatrics,n/a,1,False,False,False
4169759,100413,RxNorm:1455099,{'CYP2D6': 'Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4169656,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169657,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169658,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169659,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169660,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169661,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169662,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169675,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169663,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169664,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169665,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169666,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169667,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169668,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169669,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169670,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169671,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169672,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169673,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations 
for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",1,False,False,False
4169674,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169686,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",No recommendation,Strong,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",general,n/a,1,False,False,False
4169676,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169677,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169678,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169679,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169680,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169681,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169682,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169683,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169684,100414,RxNorm:10834,"{'CYP2D6': 'Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure', 'CYP2C19': 'n/a'}","Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169685,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169687,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169688,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169689,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169690,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169691,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,n/a,1,False,False,False
4169692,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169693,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",general,n/a,1,False,False,False
4169694,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169695,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal metabolism of tertiary amines'}",Initiate therapy with recommended starting dose.,Strong,"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169705,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,n/a,1,False,False,False
4169696,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169697,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169698,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",1,False,False,False
4169699,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",No recommendation,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",general,n/a,1,False,False,False
4169700,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Reduced metabolism of tertiary amines compared to normal metabolizers'}",Initiate therapy with recommended starting dose.,Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",general,"Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169701,100414,RxNorm:10834,"{'CYP2D6': 'n/a', 'CYP2C19': 'Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects'}","Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",Optional,"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",general,"Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",1,False,False,False
4169702,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,n/a,1,False,False,False
4169703,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,n/a,1,False,False,False
4169704,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,n/a,1,False,False,False
4169707,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,n/a,1,False,False,False
4169708,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,n/a,1,False,False,False
4169709,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,n/a,1,False,False,False
4169710,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,n/a,1,False,False,False
4169711,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,n/a,1,False,False,False
4169712,100413,RxNorm:39786,{'CYP2D6': 'Increased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and increased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal metabolizers. There is insufficient evidence supporting the clinical impact of increased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 ultrarapid metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,n/a,1,False,False,False
4169713,100413,RxNorm:39786,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4169714,100413,RxNorm:39786,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4169715,100413,RxNorm:39786,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4169716,100413,RxNorm:39786,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4169717,100413,RxNorm:39786,{'CYP2D6': 'Normal metabolism'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4169718,100413,RxNorm:39786,{'CYP2D6': 'Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4169719,100413,RxNorm:39786,{'CYP2D6': 'Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},general,n/a,1,False,False,False
4169720,100413,RxNorm:39786,{'CYP2D6': 'Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},general,n/a,1,False,False,False
4169753,100413,RxNorm:1455099,{'CYP2D6': 'Normal metabolism.'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},general,n/a,1,False,False,False
4169754,100413,RxNorm:1455099,{'CYP2D6': 'Normal metabolism.'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},general,n/a,1,False,False,False
4169721,100413,RxNorm:39786,{'CYP2D6': 'Decreased metabolism of venlafaxine to active metabolite O-desmethylvenlafaxine (desvenlafaxine) and decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to normal metabolizers. There is insufficient evidence supporting the clinical impact of the decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 intermediate metabolizers.'},No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.,No Recommendation,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},general,n/a,1,False,False,False
4169722,100413,RxNorm:39786,"{'CYP2D6': 'Decreased metabolism of venlafaxine to the active metabolite O-desmethylvenlafaxine (desvenlafaxine) and greatly decreased O-desmethylvenlafaxine:venlafaxine ratio as compared to CYP2D6 normal and intermediate metabolizers. The clinical impact of increased venlafaxine and decreased O-desmethylvenlafaxine:venlafaxine ratio in CYP2D6 poor metabolizers is unclear, but CYP2D6 PM genotype has been associated with adverse effects.'}",Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.,Optional,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169723,100413,RxNorm:39786,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
4169724,100410,RxNorm:121243,"{'CYP2C19': 'In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic concentrations is small'}",Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.,Moderate,{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.",1,False,False,False
4169725,100410,RxNorm:121243,"{'CYP2C19': 'In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is variable.'}",Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.,Moderate,{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring (TDM), and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible. Meticulous TDM is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.",1,False,False,False
4169726,100410,RxNorm:121243,{'CYP2C19': 'Normal voriconazole metabolism'},Initiate therapy with recommended standard of care dosing,Strong,{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169727,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers'},Initiate therapy with recommended standard of care dosing,Moderate,{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169728,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers'},Initiate therapy with recommended standard of care dosing,Moderate,{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169729,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events'},"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",1,False,False,False
4169730,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events'},"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",Moderate,{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},pediatrics,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",1,False,False,False
4169732,100410,RxNorm:121243,"{'CYP2C19': 'In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing'}","Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",Moderate,{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype.",1,False,False,False
4169733,100410,RxNorm:121243,"{'CYP2C19': 'In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing'}","Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",Moderate,{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169734,100410,RxNorm:121243,{'CYP2C19': 'Normal voriconazole metabolism'},Initiate therapy with recommended standard of care dosing,Strong,{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169735,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers'},Initiate therapy with recommended standard of care dosing,Moderate,{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169736,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers'},Initiate therapy with recommended standard of care dosing,Moderate,{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169737,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events'},"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",Moderate,{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169738,100410,RxNorm:121243,{'CYP2C19': 'Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events'},"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",Moderate,{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},adults,"Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",1,False,False,False
4169739,100410,RxNorm:121243,{'CYP2C19': 'n/a'},No recommendation,No Recommendation,{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},adults,n/a,1,False,False,False
4169740,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169741,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169755,100413,RxNorm:1455099,{'CYP2D6': 'Normal metabolism.'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},general,n/a,1,False,False,False
4169756,100413,RxNorm:1455099,{'CYP2D6': 'Reduced metabolism of vortioxetine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},Initiate therapy with recommended starting dose.,Moderate,{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},general,n/a,1,False,False,False
4169742,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169743,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169744,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169745,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169746,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169747,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169748,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169749,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169750,100413,RxNorm:1455099,{'CYP2D6': 'Increased metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit.'},"Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.",Optional,{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},general,"Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",1,False,False,False
4169751,100413,RxNorm:1455099,{'CYP2D6': 'Normal metabolism.'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},general,n/a,1,False,False,False
4169752,100413,RxNorm:1455099,{'CYP2D6': 'Normal metabolism.'},Initiate therapy with recommended starting dose.,Strong,{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},general,n/a,1,False,False,False
4169760,100413,RxNorm:1455099,{'CYP2D6': 'Greatly reduced metabolism of vortioxetine to inactive compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects.'},"Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6.",Moderate,{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},general,"Drug-drug interactions, indication and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.",1,False,False,False
4169761,100413,RxNorm:1455099,{'CYP2D6': 'n/a'},No recommendation,No Recommendation,{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},general,n/a,1,False,False,False
